MOG CNS Autoimmunity and MOGAD - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38996203/
At one time considered a possible form of neuromyelitis optica (NMO) spectrum disorder (NMOSD), it is now accepted that myelin oligodendrocyte glycoprotein (MOG) antibody (Ab)-associated disorder (MOGAD) is a distinct...
MOG antibody-associated disorder (MOGAD) is distinct from NMO and MS, with unclear pathogenic roles of anti-MOG antibodies. Insights from experimental models reveal evolving understanding of MOGAD's immunology.
Extracellular Vesicles in Multiple Sclerosis: Their Significance in the Development and Possible Applications as Therapeutic Agents and Biomarkers
Source : https://pubmed.ncbi.nlm.nih.gov/38927708/
Extracellular vesicles (EVs) are "micro-shuttles" that play a role as mediators of intercellular communication. Cells release EVs into the extracellular environment in both physiological and pathological conditions and are involved...
Extracellular vesicles (EVs) offer insight into multiple sclerosis (MS) pathophysiology and hold promise as biomarkers and therapeutic targets, though their full potential remains under investigation.
Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management
Source : https://pubmed.ncbi.nlm.nih.gov/38354532/
Neurofilament light chain (NfL) is a long-awaited blood biomarker that can provide clinically useful information about prognosis and therapeutic efficacy in multiple sclerosis (MS). There is now substantial evidence for...
Serum neurofilament light chain (sNfL) is a promising, noninvasive biomarker for MS management, offering frequent monitoring of disease activity and treatment efficacy, though it requires further standardization for clinical use.
Multiple Sclerosis: From the Application of Oligoclonal Bands to Novel Potential Biomarkers
Source : https://pubmed.ncbi.nlm.nih.gov/38791450/
Multiple sclerosis is a chronic immune-mediated disorder of the central nervous system with a high heterogeneity among patients. In the clinical setting, one of the main challenges is a proper...
Combining cerebrospinal fluid analysis with emerging biomarkers enhances the diagnosis and monitoring of multiple sclerosis, offering improved accuracy and potential for early disease activity prediction.
Use of pragmatic randomized trials in multiple sclerosis: A systematic overview
Source : https://pubmed.ncbi.nlm.nih.gov/38253528/
Only few and mostly small pragmatic trials exist in MS which rarely assess drugs. Despite the widely available routine data infrastructures, very few trials utilize them. There is an urgent...
Pragmatic trials in multiple sclerosis (MS) are limited, with few assessing drugs and seldom using routine data, highlighting the need for more real-world evidence studies.